AstraZeneca’s Forxiga (dapagliflozin) Receives NMPA’s Approval for Chronic Heart Failure

 AstraZeneca’s Forxiga (dapagliflozin) Receives NMPA’s Approval for Chronic Heart Failure

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

Shots:

  • The approval is based on P-III DAPA-HF trial involves assessing of Forxiga (10mg, qd) + SOC (ACEi or ARB) vs PBO + SOC in 4,744 patients with HFrEF (LVEF ≤ 40%) with/ out T2D
  • The study demonstrated 26% reduction in the risk of the composite of CV death or worsening of HF events, including hHF. The safety profile of Forxiga was consistent with the well-established safety profile of the therapy
  • Forxiga is the first SGL2 inhibitor, currently being tested for HFpEF in the DELIVER P-III trial with its anticipated data in the H1’21

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: The Scientist Magazine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post